Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Bacil Pharma Ltd Fundamentals

Market Cap
₹ 12.15 Cr
P/E Ratio (TTM)
0.00
P/B Ratio
20.95
Debt to Equity
0.02
ROE
0.00
EPS (TTM)
0.00
Dividend Yield
0.00 %
Book Value
0.98

Click here to know more about Fundamentals

Bacil Pharma Ltd Financials

Bacil Pharma Ltd Financials

Bacil Pharma Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Retail 53.89 % 53.77 % 53.80 % 53.80 %
Promoters 42.67 % 42.67 % 42.67 % 42.67 %
Others 3.44 % 3.56 % 3.53 % 3.53 %
Mutual Funds 0.00 % 0.00 % 0.00 % 0.00 %
FII 0.00 % 0.00 % 0.00 % 0.00 %

Retail

53.89%

Promoters

42.67%

Others

3.44%

Mutual Funds

0.00%

FII

0.00%

Retail

53.77%

Promoters

42.67%

Others

3.56%

Mutual Funds

0.00%

FII

0.00%

Retail

53.80%

Promoters

42.67%

Others

3.53%

Mutual Funds

0.00%

FII

0.00%

Retail

53.80%

Promoters

42.67%

Others

3.53%

Mutual Funds

0.00%

FII

0.00%

Resistance and Support

₹20.63

PIVOT

resistance-arrow
Resistance
First Resistance₹20.630
Second Resistance₹20.630
Third Resistance₹20.630
support-arrow
Support
First Support₹20.630
Second Support₹20.630
Third Support₹20.630

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day500500100.00
Week2582,2120.00
1 Month2581,4570.00
6 Months150,924150,924100.00

About Bacil Pharma Ltd

Incorporated as a private limited company in Maharashtra in May '87, Bacil Pharma (BPL) was converted into a public limited company in Oct.'90. The main business activity of the Company is Pharmaceutical. Bal Pharma is a fully integrated and leading Indian pharmaceutical company specialized in Prescription drugs, Branded Formulations, APIs, Generic & OTC products, Intravenous Infusions and Bulk Drugs. Domestic operations are spread across pan India. The company has strong field force of 500 plus, spread over various States and Districts. It has a strong distribution set up, with Super Stockist in all the States and stockists for retail coverage. To augment the domestic market, Company's operations are based on focused approach. Multi-Speciality division Vibrant specialises in various specialties, like Anti-Infectives, Pain Management, Respiratory Care, Women's Health, to name a few. Aziwin, Ebay, Balvibe, MNF, Ocium and Monogesic Plus Gel (Innovative Pain Relieving Gel, first time in India) are some of the leading brands in the respective segments. Bal Vedics Division integrates modern medicine with herbal/ayurvedic preparation targeting specific conditions like, Prostrate Enlargement, Renal Calculi, Male Infertility, Women Health etc. Bal Pharma Institutional division is associated with the top Government bodies and Hospitals to extend its product range to the masses. Every area is well covered and supplied through there channel partners. Bal Pharma Unit - 1, is a finished dosage facility for manufacturing Tablets and Capsules. Bal Pharma Unit - 2, is involved in the manufacturing of APIs. A well-equipped R&D laboratory, a good Kilo laboratory and quality control facilities form the other spheres of activity here. Bal Pharma Unit - 3, is a finished dosage facility for manufacturing Intravenous Fluids, Ophthalmic Preparations & Liquid Oral Preparations. BPL came out with a public issue of Rs 7 cr in Mar.'94 to set up a plant at Vapi to manufacture bulk drugs like atenalol, norfloxacin, pefloxacin and ciprofloxacin. The company entered into a marketing arrangement with a distributor Kam Han Industries, Hong Kong, to export 50% of the production. Due to various reasons, the civil works at Vapi were affected. However, to avoid further delay in project implementation, the company acquired from SICOM an existing bulk drug unit with necessary infrastructure and production facilities at Lote Parashuram (near Ratnagiri).

Managing Director

1987

Founded

NA

NSE Symbol

NA

Bacil Pharma Ltd Management

NameDesignation
Prakash ShahDirector
Ganpat Dhondu SalekarDirector
Shirish ShetyeIndependent Director
Parul DaveIndependent Director
Suman ShahDirector
Bhavana TakCompany Sec. & Compli. Officer

Bacil Pharma Ltd News

Bacil Pharma reports standalone net loss of Rs 0.04 crore in the March 2024 quarter
Reported sales nil
Bacil Pharma to convene board meeting
On 21 May 2024
Bacil Pharma reports standalone net loss of Rs 0.02 crore in the December 2023 quarter
Reported sales nil
Bacil Pharma to hold board meeting
On 13 February 2024
Bacil Pharma reports standalone net loss of Rs 0.01 crore in the September 2023 quarter
Reported sales nil
Bacil Pharma to declare Quarterly Result
On 10 November 2023
Bacil Pharma AGM scheduled
On 16 September 2023
Bacil Pharma reports standalone net profit of Rs 0.02 crore in the June 2023 quarter
Reported sales nil
Bacil Pharma to declare Quarterly Result
On 14 August 2023
Bacil Pharma reports standalone net loss of Rs 0.08 crore in the March 2023 quarter
Reported sales nil

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
Sun Pharmaceuticals Industries Ltd₹ 358724.57 Cr
₹ 1,495.10
(-2.87 %)
87.07
Cipla Ltd₹ 120233.22 Cr
₹ 1,489.15
(0.46 %)
32.36
Zydus Lifesciences Ltd₹ 109282.04 Cr
₹ 1,086.05
(0.50 %)
31.67
Divis Laboratories Ltd₹ 109187.23 Cr
₹ 4,113.00
(1.34 %)
80.00
Dr Reddys Laboratories Ltd₹ 98384.41 Cr
₹ 5,897.70
(0.42 %)
22.64

Bacil Pharma Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Bacil Pharma Ltd shares in BlinkX

Bacil Pharma Ltd's P/E ratio is 0.00 times as of May 23, 2024 at 04:00 PM.

Bacil Pharma Ltd's most recent financial reports indicate a price-to-book ratio of 20.95, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Bacil Pharma Ltd's market is 12 Cr as on May 23, 2024 at 04:00 PM.

The current financial records of Bacil Pharma Ltd show a 0.00% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

According to Bacil Pharma Ltd's most recent financial filings, the company has a total asset value of Crores, which includes current and non-current assets such as inventory, cash, properties, and equipment.

As of the Mar 2024 quarter, the promoter shareholding in Bacil Pharma Ltd stands at 42.67%. During the same period, Institutional Investors have shown a slight values are equal in their holdings, values are equal from 0.00% to 0.00%.